

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FORTY-FOURTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM MAY 1, 2023 THROUGH MAY 31, 2023**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	May 1, 2023 through May 31, 2023
Monthly Fees Incurred:	\$56,710.50

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$56,710.50

This is a: X monthly \_\_\_\_\_interim \_\_\_\_\_final application

**PRIOR APPLICATIONS:**

<b>Docket No./Filed</b>	<b>Compensation Period</b>	<b>Requested</b>		<b>Approved</b>	
		<b>Fees</b>	<b>Expenses</b>	<b>Fees</b>	<b>Expenses</b>
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94

**PRIOR APPLICATIONS (cont.):**

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$178,888.84	\$8.00
Docket No. 4826 Filed on 5/16/2022	3/1/2022 – 3/31/2022	\$267,504.00	\$44.03	\$265,194.33	\$44.03
Docket No. 4833 Filed on 5/16/2022	4/1/2022 – 4/30/2022	\$175,704.00	\$0.00	\$173,394.33	\$0.00
Docket No. 4950 Filed on 7/12/2022	5/1/2022 – 5/31/2022	\$98,099.50	\$0.00	\$96,849.50	\$0.00
Docket No. 5005 Filed on 8/8/2022	6/1/2022 – 6/30/2022	\$53,624.00	\$0.00	\$52,374.00	\$0.00
Docket No. 5051 Filed on 8/31/2022	7/1/2022 – 7/31/2022	\$53,023.00	\$0.00	\$51,773.00	\$0.00
Docket No. 5132 Filed on 10/12/2022	8/1/2022 – 8/31/2022	\$35,470.00	\$0.00	\$34,220.00	\$0.00
Docket No. 5240 Filed on 11/15/2022	9/1/2022 – 9/30/2022	\$53,219.00	\$8.00	\$52,344.00	\$8.00
Docket No. 5341 Filed on 1/13/2023	10/1/2022 – 10/31/2022	\$30,107.50	\$0.00	\$29,232.50	\$0.00
Docket No. 5342 Filed on 1/13/23	11/1/2022 – 11/30/2022	\$31,105.00	\$0.00	\$30,230.00	\$0.00
Docket No. 5393 Filed on 2/1/23	12/1/2022 – 12/31/2022	\$42,190.00	\$0.00	\$41,315.00	\$0.00
Docket No. 5518 Filed on 3/30/23	1/1/2023 – 1/31/2023	\$98,523.50	\$0.00	\$78,818.80	\$0.00
Docket No. 5519 Filed on 3/30/23	2/1/2023 – 2/28/2023	\$125,875.00	\$0.00	\$100,700.00	\$0.00
Docket No. 5599 Filed on 5/12/23	3/1/2023 – 3/31/2023	\$91,292.50	\$0.00	\$73,034.00	\$0.00
Docket No. 5705 Filed on 6/14/23	4/1/2023 – 4/30/2023	\$103,758.50	\$0.00	\$83,006.80	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, \$6,000, \$6,929, \$5,000, and \$3,500 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from May 1, 2023 through and including May 31, 2023 (the “**Fee Period**”) amount to:

Professional Fees	\$56,710.50
Expenses	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$56,710.50</u></b>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$45,368.40
Expenses at 100%	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$45,368.40</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than July 28, 2023 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
July 14, 2023

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
1166 Avenue of the Americas, 15<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY PROFESSIONAL****FOR THE PERIOD MAY 1, 2023 TO MAY 31, 2023**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate</b>	<b>Total Hours</b>	<b>Total Fees</b>
Matthew Diaz	Sr Managing Director	Restructuring	\$ 1,325	13.0	\$ 17,225.00
Steven Joffe	Sr Managing Director	Tax	1,325	0.7	927.50
Brian Bromberg	Managing Director	Restructuring	985	13.0	12,805.00
Emma Kurtz	Director	Restructuring	835	24.3	20,290.50
Jack Blittner	Consultant	Restructuring	475	11.5	5,462.50
<b>GRAND TOTAL</b>				<b>62.5</b>	<b>\$ 56,710.50</b>

**EXHIBIT B****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD MAY 1, 2023 TO MAY 31, 2023**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	3.7	\$ 2,241.50
2	Cash & Liquidity Analysis	1.4	1,855.00
6	Asset Sales	1.4	1,855.00
7	Analysis of Domestic Business Plan	6.0	5,600.00
9	Analysis of Employee Comp Programs	1.0	1,087.00
10	Analysis of Tax Issues	0.7	927.50
16	Analysis, Negotiate and Form of POR & DS	35.5	33,653.50
21	General Mtgs with Counsel and/or Ad Hoc Committee	4.5	4,282.50
24	Preparation of Fee Application	8.3	5,208.50
<b>GRAND TOTAL</b>		<b>62.5</b>	<b>\$ 56,710.50</b>

## EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MAY 1, 2023 TO MAY 31, 2023

Task Category	Date	Professional	Hours	Activity
1	5/2/2023	Jack Blittner	0.4	Prepare the 5/2 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/8/2023	Jack Blittner	0.3	Prepare the 5/8 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/11/2023	Emma Kurtz	0.4	Review latest dataroom updates re: reporting.
1	5/11/2023	Jack Blittner	0.4	Prepare the 5/11 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/23/2023	Jack Blittner	0.6	Prepare the 5/23 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/23/2023	Matthew Diaz	0.4	Review summary of hearings to assess the Debtors' current operational and financial status.
1	5/25/2023	Jack Blittner	0.3	Prepare the 5/25 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/30/2023	Jack Blittner	0.7	Prepare the 5/30 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	5/31/2023	Jack Blittner	0.2	Prepare the 5/31 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
<b>1 Total</b>			<b>3.7</b>	
2	5/2/2023	Matthew Diaz	0.8	Review latest cash reporting from the Debtors to assess the Debtors' liquidity status.
2	5/23/2023	Matthew Diaz	0.6	Review updated cash reporting from the Debtors to assess the Debtors' liquidity status.
<b>2 Total</b>			<b>1.4</b>	
6	5/1/2023	Matthew Diaz	0.5	Participate in call with Counsel re: Avrio sale proceeds.
6	5/1/2023	Matthew Diaz	0.3	Participate in call with the Debtors re: Avrio sale proceeds.
6	5/22/2023	Matthew Diaz	0.6	Review the Committee's statement on the Avrio sale.
<b>6 Total</b>			<b>1.4</b>	
7	5/2/2023	Matthew Diaz	0.5	Participate in call with the Debtors' professionals re: key case issues and business plan updates.
7	5/3/2023	Brian Bromberg	0.3	Finalize updated business plan diligence list to be sent to the Debtors.
7	5/14/2023	Brian Bromberg	0.9	Evaluate latest business plan projections based on discussions the Debtors' professionals.
7	5/16/2023	Brian Bromberg	0.4	Participate in call with the Debtors' professionals re: business plan projections and updates, and emergence preparations.
7	5/16/2023	Emma Kurtz	0.4	Participate in call with the Debtors' professionals re: business plan projections and updates.
7	5/22/2023	Brian Bromberg	0.3	Review pipeline updates to assess the projected spend.
7	5/22/2023	Emma Kurtz	0.7	Prepare summary notes for team re: pipeline call.
7	5/22/2023	Emma Kurtz	0.6	Review materials from the Debtors to prepare for pipeline update call.
7	5/22/2023	Emma Kurtz	1.5	Participate in call with the Debtors' professionals re: pipeline products status.
7	5/30/2023	Brian Bromberg	0.4	Participate in call with Debtors re: business plan updates.
<b>7 Total</b>			<b>6.0</b>	
9	5/1/2023	Brian Bromberg	0.3	Prepare correspondence with Counsel re: 2023 KEIP proposal.
9	5/1/2023	Matthew Diaz	0.3	Attend call with Alix to discuss the KEIP.
9	5/3/2023	Brian Bromberg	0.4	Review draft update for the committee re: KEIP/KERP to prepare revisions.
<b>9 Total</b>			<b>1.0</b>	
10	5/31/2023	Steven Joffe	0.7	Review the second circuit court decision to assess potential tax implications.
<b>10 Total</b>			<b>0.7</b>	
16	5/1/2023	Brian Bromberg	1.0	Participate in call with internal team re: Avrio proceeds and updated distributable value analysis.
16	5/1/2023	Brian Bromberg	0.4	Review Avrio sale proceeds to assess potential implications for the Committee.
16	5/1/2023	Brian Bromberg	0.6	Review analysis of impact of Avrio sale on distributions.
16	5/1/2023	Brian Bromberg	1.2	Review updated distributable value analysis to provide feedback to team.
16	5/1/2023	Emma Kurtz	1.4	Prepare revisions to presentation re: impact of Avrio sale proceeds per comments from team.
16	5/1/2023	Emma Kurtz	1.0	Participate in call with the internal team re: incentive compensation, Avrio proceeds, and distributable value update.
16	5/1/2023	Emma Kurtz	2.7	Prepare analysis of potential Avrio sale proceeds to update distributable value model.
16	5/1/2023	Emma Kurtz	3.1	Prepare presentation re: potential Avrio sale proceeds based on updated distributable value model.
16	5/1/2023	Jack Blittner	0.5	Participate (partially) in call with the internal team re: incentive compensation, Avrio proceeds, and distributable value update.
16	5/1/2023	Jack Blittner	1.1	Prepare slides summarizing Avrio bid procedure motion.

## EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MAY 1, 2023 TO MAY 31, 2023

Task Category	Date	Professional	Hours	Activity
16	5/1/2023	Jack Blittner	0.4	Continue to prepare slides summarizing Avrio sale process and treatment of proceeds.
16	5/1/2023	Matthew Diaz	0.6	Review draft slides re: distributable value analysis.
16	5/1/2023	Matthew Diaz	1.3	Review updated emergence cash flows analysis to provide comments to team.
16	5/2/2023	Brian Bromberg	0.5	Participate in call with the Debtors' professional re: business plan updates, 2023 KEIP proposal, and emergence considerations.
16	5/2/2023	Brian Bromberg	0.7	Review slides covering the Avrio sale and impact on distributions to provide comments to team.
16	5/2/2023	Emma Kurtz	0.5	Participate in call with the Debtors' professional re: business plan updates, emergence considerations, and case status.
16	5/2/2023	Matthew Diaz	1.4	Review updated emergence cash flows analysis based on latest case updates.
16	5/3/2023	Emma Kurtz	1.7	Prepare revised presentation re: Accord trial and distributable value updates.
16	5/3/2023	Emma Kurtz	1.9	Prepare updates to distributable value model to reflect latest assumptions and draft revised summary charts.
16	5/3/2023	Matthew Diaz	0.7	Assess recovery analysis scenarios to evaluate potential implications for the Committee.
16	5/4/2023	Brian Bromberg	0.2	Continue to assess recovery analysis scenarios to evaluate potential implications for the Committee.
16	5/4/2023	Brian Bromberg	0.9	Review slides summarizing updated business plan projections to provide feedback to the team.
16	5/4/2023	Emma Kurtz	1.8	Prepare revisions to presentation re: Accord and distributable value update per comments from the internal team.
16	5/4/2023	Emma Kurtz	0.6	Provide guidance to the internal team re: updates to distributable value model.
16	5/8/2023	Brian Bromberg	0.7	Review slides summarizing updated emergence and post-emergence distributions to provide additional comments to the team.
16	5/8/2023	Matthew Diaz	1.2	Review updated distributable value analysis to provide feedback to the internal team.
16	5/10/2023	Emma Kurtz	1.6	Prepare revisions to Accord and distributable value update presentation per comments.
16	5/11/2023	Matthew Diaz	1.1	Review updated recovery analysis to provide feedback to the internal team.
16	5/30/2023	Brian Bromberg	0.4	Review Sackler settlement agreement to assess potential recovery implications for the Committee.
16	5/30/2023	Brian Bromberg	0.3	Review prior emergence presentation to evaluate potential updates due to second circuit decision.
16	5/30/2023	Brian Bromberg	0.8	Review second circuit decision to evaluate potential implications.
16	5/30/2023	Matthew Diaz	0.6	Review Second Circuit Order to assess potential implications for the Committee.
16	5/31/2023	Brian Bromberg	0.7	Review memo from counsel re: potential case timeline following second circuit decision.
16	5/31/2023	Brian Bromberg	0.6	Review plan documents to assess implications of second circuit decision.
16	5/31/2023	Emma Kurtz	1.3	Review appeal ruling and summary from counsel re: case timing and next steps.
<b>16 Total</b>			<b>35.5</b>	
21	5/2/2023	Matthew Diaz	0.5	Participate in call with the working group re: key case issues and next steps.
21	5/31/2023	Brian Bromberg	1.0	Participate on call with the Committee re: Second Circuit ruling and potential next steps.
21	5/31/2023	Emma Kurtz	1.0	Participate on call with the Committee re: appeal ruling and potential next steps.
21	5/31/2023	Jack Blittner	1.0	Participate on call with the Committee re: Second Circuit decision and next steps.
21	5/31/2023	Matthew Diaz	1.0	Participate in call with the Committee re: Second Circuit Ruling, case status, and next steps.
<b>21 Total</b>			<b>4.5</b>	
24	5/12/2023	Emma Kurtz	0.3	Finalize March fee application for filing.
24	5/23/2023	Jack Blittner	0.7	Revise the April fee application task descriptions to ensure compliance with Bankruptcy Code.
24	5/23/2023	Jack Blittner	0.1	Continue to prepare April fee application to comply with bankruptcy code.
24	5/23/2023	Jack Blittner	0.6	Prepare April fee application to comply with bankruptcy code.
24	5/23/2023	Jack Blittner	2.3	Begin to prepare draft April fee application per local rules.
24	5/24/2023	Emma Kurtz	1.4	Review draft April fee statement fee detail.
24	5/24/2023	Jack Blittner	0.3	Prepare April Fee application exhibits to comply with bankruptcy code.
24	5/25/2023	Emma Kurtz	0.4	Review draft April fee application exhibits and statement.
24	5/25/2023	Jack Blittner	1.3	Continue to prepare April fee application exhibits to comply with bankruptcy code.
24	5/25/2023	Jack Blittner	0.3	Finalize draft of April fee application to be sent to Counsel.
24	5/25/2023	Matthew Diaz	0.6	Review draft April fee application.
<b>24 Total</b>			<b>8.3</b>	
<b>Grand Total</b>			<b>62.5</b>	